Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Holdings Lowered by Sava Infond d.o.o.

Sava Infond d.o.o. lowered its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,570 shares of the pharmaceutical company’s stock after selling 60 shares during the quarter. Sava Infond d.o.o.’s holdings in Vertex Pharmaceuticals were worth $761,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in VRTX. Brighton Jones LLC raised its holdings in shares of Vertex Pharmaceuticals by 15.0% during the fourth quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock valued at $1,783,000 after acquiring an additional 579 shares during the period. First Horizon Advisors Inc. raised its holdings in shares of Vertex Pharmaceuticals by 1.7% during the fourth quarter. First Horizon Advisors Inc. now owns 2,199 shares of the pharmaceutical company’s stock valued at $886,000 after acquiring an additional 36 shares during the period. World Equity Group Inc. acquired a new stake in shares of Vertex Pharmaceuticals during the fourth quarter valued at approximately $234,000. Union Bancaire Privee UBP SA acquired a new stake in shares of Vertex Pharmaceuticals during the fourth quarter valued at approximately $56,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Vertex Pharmaceuticals during the fourth quarter valued at approximately $2,169,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

VRTX stock opened at $443.54 on Tuesday. The company has a quick ratio of 2.29, a current ratio of 2.65 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $113.90 billion, a price-to-earnings ratio of -113.15 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88. The firm has a 50 day moving average of $458.17 and a two-hundred day moving average of $459.38.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing the consensus estimate of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The business had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.85 billion. During the same period in the prior year, the firm earned $4.76 earnings per share. The business’s revenue was up 2.6% on a year-over-year basis. As a group, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on VRTX shares. HC Wainwright restated a “buy” rating and set a $550.00 price target on shares of Vertex Pharmaceuticals in a report on Monday. Wall Street Zen raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, March 11th. William Blair reaffirmed an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Morgan Stanley lowered their price objective on shares of Vertex Pharmaceuticals from $464.00 to $460.00 and set an “equal weight” rating on the stock in a research report on Friday. Finally, Bank of America boosted their price objective on shares of Vertex Pharmaceuticals from $555.00 to $567.00 and gave the company a “buy” rating in a research report on Monday, March 31st. Fourteen equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $513.14.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.